Foghorn Therapeutics Inc. (FHTX)
NGM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 7.6M | 8.2M | 9.2M | 3.3M |
| Operating Income | -21.1M | -18.5M | -19.6M | -21.6M |
| Net Income | -17.9M | -15.8M | -21.7M | -19.9M |
| Diluted EPS | $-0.28 | $-0.25 | $nan | $-0.29 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 19.2M | 34.2M | 22.6M | 30.9M |
| Operating Income | -117.1M | -107.9M | -100.3M | -82.1M |
| Net Income | -108.9M | -98.4M | -86.6M | -74.3M |
| Diluted EPS | $-2.62 | $-2.34 | $-1.58 | $nan |